Answers are grounded in this paper and cite their sources.
Analysis shows mineralocorticoid receptor antagonists result in modest weight loss in hypertensive patients, implying a complex link with obesity.
Introduction: There is an established link between aldosterone and obesity. Paradoxically, in primary aldosteronism (PA), unilateral PA manifests more aldosterone dysregulation (higher circulating aldosterone levels, greater 24-hour urine aldosterone excretion) than bilateral PA, yet the latter PA phenotype is significantly more obese. Also, the relationship between obesity and aldosterone could conceivably arise in several ways: 1) adipocytes synthesize and release several aldosterone secretagogues that stimulate adrenal aldosterone synthesis, 2) adipocytes can synthesize aldosterone, and 3) mineralocorticoid receptor (MR) activation in adipocytes causes expansion of adipocyte mass. Thus, we undertook an analysis to determine the magnitude of weight loss caused by pharmacological blockade of the mineralocorticoid receptor (MR) and, if detected, was the weight loss sustained over time. Methods: The Southern Illinois University School of Medicine’s electronic health record was queried to identify patients with HTN and continuous MR antagonist (MRA) prescription for ≥ 6 months. Weight/BMI data was collected from ≤ 6 months before and ≥ 6 months after initiating MRA treatment. Patients prescribed weight loss medications and those with prior history of bariatric surgery were excluded. We determined median (interquartile range) weight change between 0-6 months before initiation of the MRA as well as at 1-3, 3-6, 6-12, 12-18 and 18-24 months after initiation of the MRA. Analyses were separately performed in obese (BMI > 30 kg/m2) and severely obese (BMI > 40 kg/m2) patients. Results: In total, 1,202 patients with HTN and a requisite history of MRA use were identified with, respectively, 788 and 288 in the obese and severely obese cohorts. Overall, median weight change ranged from -0.4 kg (-2.7, 1.5) at 1-3 months to -0.7 kg (-5.0, 3.0) at 18-24 months while weight changes in the obese and severely obese cohort ranged from -0.5 kg (-3.0, 1.6) to -1.0 kg (-6.0, 3.6) and from -0.9 kg (-4.0, 1.5) to -1.8 (-7.7, 3.0) over the same follow-up intervals. The observed weight changes after initiation of MRAs did not vary to a statistically significant degree over time (p = 0.7). Conclusion: There were small reductions in weight among obese and severely obese patients with HTN prescribed MRAs. Our findings were more consistent with obesity causing aldosterone excess than MR activation causing obesity.
No takes yet. Share an insight, caveat, or question.
Yaganti et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: